Skip to main content
Premium Trial:

Request an Annual Quote

Intrexon Prices Public Offering Targeting $200M

NEW YORK (GenomeWeb) – Intrexon today priced a public offering of almost 4.9 million shares of its common stock aimed at raising $200 million in gross proceeds. 

The Germantown, Maryland-based synthetic biology firm is offering 4,878,049 shares of its stock at $41 per share. Proceeds from the offering will go toward general corporate purposes and strategic acquisitions or investments, it said. 

JMP Securities is the sole book-running manager while Stifel is the lead manager on the offering. Griffin Securities and Wunderlich Securities are the co-managers. Intrexon has granted the underwriters a 30-day option to purchase up to an additional 731,707 shares. 

In afternoon trading, Intrexon shares rose 8 percent on the New York Stock Exchange to $45.94.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.